Specialised Therapeutics Asia

Specialised Therapeutics Asia is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Specialised Therapeutics Asia. Specialised Therapeutics is an international, independent pharmaceutical company providing new specialist medicines to patients in Australia, New Zealand and South East Asia. Founded in 2008 by international pharmaceutical executives Carlo Montagner and Bozena Zembrzuski, Specialised Therapeutics began with a single oncology product that is now one of the most successful branded chemotherapies ever commercialised in Australia. Since its inception, the ST product portfolio has rapidly expanded, and now spans oncology, haematology, neurology, supportive care, genomic assays and ophthalmology. Headquartered in Singapore, with representative offices in Australia and New Zealand, the ST business strategy has always been to prudently select high-calibre global pharmaceutical partners, and champion their products from pre-registration to full commercialisation in key AU, NZ and SE Asia regions. Every member of the ST team brings extensive experience, predominantly gained in global pharmaceutical companies. This deep expertise means ST has the capability to expertly and strategically navigate complex regulatory and reimbursement pathways in diverse markets. As a result, it has a very successful track record of commercialising specialised products. While the company has evolved, its mission is unwavering: to provide patients with innovative therapies and technologies that fulfill unmet specialised medical needs. Current international partners include: • Celgene Corporation • Puma Biotechnology • Helsinn Healthcare • photonamic GmbH • Takeda Pharmaceuticals • Genomic Health Inc • Alimera Sciences Inc • Pharma Mar In essence, we are: • PASSIONATE about delivering breakthrough healthcare to patients in Australia, New Zealand and South East Asia • DEDICATED to representing our partners and their products with a high level of commitment • INSPIRED by new technologies that promise to improve disease management • COMMITTED to developing new relationships with international partners to provide ‘specialised therapeutics’ that will change lives • DETERMINED to make a difference.